Stock Scorecard

Stock Summary for Regeneron Pharmaceuticals Inc (REGN) - $586.00 as of 10/8/2025 4:34:17 PM EST

Total Score

20 out of 30

Safety Score

61 out of 100

Currently on the following lists
Dividend Stock List
Tim's Recommendation
Buy

Growth List Algorithm Criteria for REGN

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for REGN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for REGN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for REGN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for REGN (61 out of 100)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 0
Book Value (Max of 10) 10
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 1
Operating Margin (Max of 10) 6
Trading Volume (Max of 10) 6
Price to Earnings (Max of 10) 9
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for REGN

Libtayo® ( cemiplimab-rwlc ) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma ( CSCC ) with a High Risk of Recurrence After Surgery and Radiation - Regeneron Pharmaceuticals ( NASDAQ:REGN ) 10/8/2025 6:31:00 PM
Libtayo® ( cemiplimab-rwlc ) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma ( CSCC ) with a High Risk of Recurrence After Surgery and Radiation 10/8/2025 6:31:00 PM
1 Stock Up by 63% This Year That Could Double, According to Wall Street 10/7/2025 1:45:00 PM
A Look Into Regeneron Pharmaceuticals Inc's Price Over Earnings - Regeneron Pharmaceuticals ( NASDAQ:REGN ) 10/3/2025 2:02:00 PM
Nvidia, Amphenol, Lockheed Martin And A Health Care Stock On CNBC's 'Final Trades' - Lockheed Martin ( NYSE:LMT ) , Amphenol ( NYSE:APH ) 10/1/2025 2:10:00 PM
Acuity, Lithium Americas, Rezolve AI, AES And Other Big Stocks Moving Higher On Wednesday - Acuity ( NYSE:AYI ) , AES ( NYSE:AES ) 10/1/2025 1:57:00 PM
Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025 9/30/2025 8:05:00 PM
Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025 - Regeneron Pharmaceuticals ( NASDAQ:REGN ) 9/30/2025 8:05:00 PM
2 Beaten-Down Stocks to Buy and Hold for a Decade 9/30/2025 11:30:00 AM
FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza 9/29/2025 12:28:00 PM

Financial Details for REGN

Company Overview
Ticker REGN
Company Name Regeneron Pharmaceuticals Inc
Country USA
Description Regeneron Pharmaceuticals, Inc. is a leading American biotechnology company based in Westchester County, New York, known for its innovative research and development in the field of monoclonal antibodies and therapeutic proteins. Established initially to explore neurotrophic factors, Regeneron has successfully expanded its focus to include a broad array of therapeutic areas, including oncology, ophthalmology, and immunology, highlighted by its flagship products such as Eylea and Dupixent. The company's robust pipeline and commitment to scientific advancement position it as a key player in the biopharmaceutical industry, with a strong track record of delivering novel therapies to address unmet medical needs.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 6/30/2025
Next Earnings Date 10/30/2025

Stock Price History
Last Day Price 586.00
Price 4 Years Ago 628.86
Last Day Price Updated 10/8/2025 4:34:17 PM EST
Last Day Volume 656,378
Average Daily Volume 1,076,777
52-Week High 1,019.99
52-Week Low 475.77
Last Price to 52 Week Low 23.17%

Valuation Measures
Trailing PE 14.75
Industry PE 22.22
Sector PE 41.70
5-Year Average PE 17.58
Free Cash Flow Ratio 30.58
Industry Free Cash Flow Ratio 14.45
Sector Free Cash Flow Ratio 30.25
Current Ratio Most Recent Quarter 4.60
Total Cash Per Share 19.16
Book Value Per Share Most Recent Quarter 287.55
Price to Book Ratio 2.12
Industry Price to Book Ratio 29.58
Sector Price to Book Ratio 32.02
Price to Sales Ratio Twelve Trailing Months 4.37
Industry Price to Sales Ratio Twelve Trailing Months 44.16
Sector Price to Sales Ratio Twelve Trailing Months 20.22
Analyst Buy Ratings 15
Analyst Strong Buy Ratings 4

Share Statistics
Total Shares Outstanding 104,170,000
Market Capitalization 61,043,620,000
Institutional Ownership 90.24%

Dividends
Ex-Dividend Date 8/18/2025
Previous Dividend Amount 0.8800
Current Dividend Amount 0.8800
Total Years Dividend Increasing 0
Trailing Annual Dividend Rate 2.64
Trailing Annual Dividend Yield 0.45%
Forward Annual Dividend Rate 3.52
Forward Annual Dividend Yield 0.60%
5-Year Dividend Payments Count 3
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio 6.65%

Income Statement
Quarterly Earnings Growth YOY 3.20%
Annual Earnings Growth 11.61%
Reported EPS 12 Trailing Months 39.70
Reported EPS Past Year 21.11
Reported EPS Prior Year 45.64
Net Income Twelve Trailing Months 4,458,600,000
Net Income Past Year 4,412,600,000
Net Income Prior Year 3,953,600,000
Quarterly Revenue Growth YOY 3.60%
5-Year Revenue Growth 12.55%
Operating Margin Twelve Trailing Months 29.60%

Balance Sheet
Total Cash Most Recent Quarter 1,995,800,000
Total Cash Past Year 2,488,200,000
Total Cash Prior Year 2,730,000,000
Net Cash Position Most Recent Quarter 10,700,000
Net Cash Position Past Year 503,800,000
Long Term Debt Past Year 1,984,400,000
Long Term Debt Prior Year 1,982,900,000
Total Debt Most Recent Quarter 1,985,100,000
Equity to Debt Ratio Past Year 0.94
Equity to Debt Ratio Most Recent Quarter 0.94
Total Stockholder Equity Past Year 29,353,600,000
Total Stockholder Equity Prior Year 25,973,100,000
Total Stockholder Equity Most Recent Quarter 29,938,900,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months 3,844,600,000
Free Cash Flow Per Share Twelve Trailing Months 36.91
Free Cash Flow Past Year 3,664,600,000
Free Cash Flow Prior Year 3,667,600,000

Options
Put/Call Ratio 0.75
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 0.00
MACD Signal 0.00
20-Day Bollinger Lower Band 0.00
20-Day Bollinger Middle Band 0.00
20-Day Bollinger Upper Band 0.00
Beta 0.31
RSI 0.00
50-Day SMA 0.00
150-Day SMA 0.00
200-Day SMA 0.00

System
Modified 10/7/2025 8:11:47 AM EST